Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says
You may also be interested in...
Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events
Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector
Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events
Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector
St. Jude’s Epic Year Wins Over Investors; MDDI Index Up 15% In 2004
St. Jude Medical's entry into the cardiac resynchronization therapy ICD market and expanded atrial fibrillation business helped capture the attention of Wall Street and potential suitors in 2004 as its stock jumped 37% for the year